CG OncologyCG Onoclogy raised almost $400 million U.S. and has a valuation of over $1 Billion U.S.
Oncolytics Biotech rasied $15 million U.S. (six months ago with the help of a predatory hedge fund that shorted shares ahead of the private placement and decimated shareholder value). Oncolytics Biotech has a valuation of under $100 Million U.S.
Here's the primary differences:
CG is currently enrolling patients in two different phase 3 trials (for bladder cancer).
ONC has talked about a phase 3 in breast cancer for the past five yeaas and has talked about a phase 3 in panc for more than one year. Neither have been submitted for registration with the FDA and ONC does not have the necessary capital to run on their own, neither do they have interest from big pharma.
CG has a strong c-suite.
ONC has Matt Coffey.
CG has a clean track record of successful prior trials in one well focused indication.
ONC has a 25 year history of failed and marginal results in more than a dozen different cancers (brain, prostate, melanoma, head and neck, ovarian, etc., just think of any part of the body and they've shown pelareorep does not work) and ONC has also demonstrated that pelareorep is ineffective when combined with at least ten different drugs. ONC went so far as to "rebrand" their product and change the name (Reolysin became Pelareorep) so as to sweep twenty years of failed trial history under the rug and hope no one does their homework.
CG is waiting for resutlts from their two phase 3 trials.
ONC is waiting for the phone to ring, hoping like hell that a hail mary offer is on the line.